Profile data is unavailable for this security.
About the company
RPG Life Sciences Limited is an India-based pharmaceutical company. The Company operates in the domestic and international markets in the formulations, generics, and synthetic active pharmaceutical ingredients (APIs) space. Its business portfolio includes domestic formulations, international formulations and APIs. Its domestic formulation business manufactures and markets-branded finished dosage formulations in India. The domestic formulations business has presence in over 10 therapeutic areas including nephrology, oncology, respiratory, vitamins and minerals, gastrointestinal and pain management, among others. The international formulations business operates in the generics and branded generics space across the regulated and emerging markets. Its branded generics space focuses on therapeutic areas, including nephrology, gastroenterology, and complex vertebral malformation (CVM) disorders. The API product line offers a range of synthetic APIs in the general therapeutic category.
- Revenue in INR (TTM)4.98bn
- Net income in INR648.10m
- Incorporated2007
- Employees1.17k
- LocationRPG Life Sciences LimitedRPG House463, Dr. Annie Besant Road, WorliMUMBAI 400030IndiaIND
- Phone+91 2 224981650
- Fax+91 2 224970127
- Websitehttp://www.rpglifesciences.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jagsonpal Pharmaceuticals Ltd | 2.25bn | 204.13m | 7.69bn | -- | 37.70 | -- | 35.32 | 3.42 | 7.79 | 7.79 | 85.90 | -- | -- | -- | -- | -- | -- | 5.39 | -- | 6.85 | 60.36 | 58.22 | 9.08 | 4.60 | -- | 98.92 | -- | 38.85 | 15.77 | 8.44 | 10.54 | 9.71 | -28.93 | 109.13 |
| NGL Fine-Chem Ltd | 2.82bn | -817.29m | 7.77bn | 329.00 | -- | -- | -- | 2.75 | -132.29 | -132.29 | 457.23 | -- | -- | -- | -- | 8,580,666.00 | -- | 17.96 | -- | 24.18 | 13.77 | 48.76 | -28.95 | 14.83 | -- | -63.53 | -- | 2.93 | 23.08 | 24.42 | -12.03 | 27.37 | 22.93 | -- |
| Medicamen Biotech Ltd | 1.25bn | 137.00m | 7.83bn | 357.00 | 56.22 | -- | 39.21 | 6.27 | 11.01 | 11.01 | 100.53 | -- | -- | -- | -- | 3,500,164.00 | -- | 8.02 | -- | 11.97 | 51.22 | 33.66 | 10.97 | 10.62 | -- | 6.12 | -- | 9.01 | 2.42 | 6.96 | 22.82 | 23.62 | 29.99 | 0.00 |
| Bliss GVS Pharma Ltd | 7.34bn | 871.47m | 7.88bn | 750.00 | 9.22 | -- | 6.87 | 1.07 | 8.21 | 8.21 | 69.11 | -- | -- | -- | -- | 9,784,959.00 | -- | 7.11 | -- | 9.87 | 48.31 | 36.87 | 13.18 | 10.68 | -- | 16.38 | -- | 11.79 | 29.50 | 12.91 | -78.04 | -6.36 | -6.52 | -3.58 |
| Bajaj Healthcare Ltd | 6.91bn | 569.04m | 9.08bn | 1.05k | 15.96 | -- | 11.20 | 1.32 | 20.62 | 20.62 | 250.20 | -- | -- | -- | -- | 6,564,269.00 | -- | 11.38 | -- | 19.70 | 26.47 | 25.65 | 8.24 | 8.64 | -- | 4.44 | -- | -- | 3.49 | 24.14 | -14.11 | 55.61 | 50.96 | -- |
| Suven Life Sciences Ltd | 151.49m | -1.11bn | 10.48bn | 117.00 | -- | -- | -- | 69.17 | -6.67 | -6.67 | 0.9369 | -- | -- | -- | -- | 1,294,812.00 | -- | -9.45 | -- | -10.92 | 76.64 | 65.15 | -735.49 | -19.84 | -- | -360.85 | -- | -- | -12.12 | -53.49 | -69.08 | -- | -8.33 | -- |
| Themis Medicare Ltd | 3.54bn | 584.45m | 11.03bn | 1.15k | 18.90 | -- | 16.09 | 3.12 | 63.41 | 63.41 | 384.11 | -- | -- | -- | -- | 3,091,841.00 | -- | 7.88 | -- | 13.03 | 66.86 | 59.46 | 16.51 | 10.95 | -- | -- | -- | 6.39 | 71.07 | 11.78 | 104.13 | 35.49 | 30.56 | -- |
| RPG Life Sciences Limited | 4.98bn | 648.10m | 11.85bn | 1.17k | 18.27 | -- | 14.77 | 2.38 | 39.20 | 39.20 | 301.24 | -- | -- | -- | -- | 4,275,708.00 | -- | 10.28 | -- | 14.95 | 66.36 | 61.70 | 13.01 | 7.69 | -- | 265.31 | -- | 27.43 | 13.11 | 7.49 | 28.70 | 33.61 | -15.58 | 27.94 |
| TTK Health Care Ltd | 7.04bn | 284.73m | 12.27bn | 2.59k | 43.08 | -- | 29.27 | 1.74 | 20.16 | 448.26 | 498.06 | -- | -- | -- | -- | 2,718,869.00 | -- | 5.08 | -- | 8.37 | 51.26 | 56.70 | 4.05 | 3.76 | -- | 1.52 | -- | 34.31 | 25.88 | 2.57 | -49.68 | -0.2463 | 3.72 | 14.87 |
| Morepen Laboratories Ltd | 14.22bn | 427.58m | 12.83bn | 2.38k | 30.00 | -- | 18.18 | 0.9022 | 0.8367 | 0.8367 | 27.43 | -- | -- | -- | -- | 5,980,358.00 | -- | 8.25 | -- | 17.08 | 32.72 | 33.95 | 3.01 | 5.86 | -- | 24.75 | -- | 0.00 | 30.20 | 21.04 | 4.73 | 33.89 | 46.89 | -- |
| Solara Active Pharma Sciences Ltd | 14.24bn | -240.60m | 13.07bn | 2.25k | -- | -- | 14.79 | 0.9179 | -6.69 | -6.69 | 391.54 | -- | -- | -- | -- | 6,317,702.00 | -- | -- | -- | -- | 41.68 | -- | -1.70 | -- | -- | -0.1553 | -- | -- | -21.56 | -- | -126.26 | -- | -- | -- |
| Novartis India Ltd | 4.01bn | 549.70m | 13.75bn | 81.00 | 25.01 | -- | 22.81 | 3.43 | 22.26 | 22.26 | 162.31 | -- | -- | -- | -- | 49,497,530.00 | -- | 3.13 | -- | 3.97 | 48.86 | 57.42 | 13.71 | 7.18 | -- | 31.51 | -- | 75.56 | 4.86 | -9.43 | -117.80 | -- | -29.15 | 0.00 |
| Hester Biosciences Ltd | 2.55bn | 298.19m | 14.27bn | 584.00 | 47.49 | -- | 27.56 | 5.59 | 35.33 | 35.33 | 293.92 | -- | -- | -- | -- | 4,370,908.00 | -- | 9.77 | -- | 12.19 | 72.20 | 70.76 | 12.27 | 17.84 | -- | 3.05 | -- | 24.00 | 9.65 | 13.38 | 14.20 | 10.80 | 25.91 | 13.54 |
| Supriya Lifescience Ltd | 5.07bn | 978.40m | 15.05bn | -- | 15.38 | -- | 13.78 | 2.97 | 12.16 | 12.16 | 63.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 59.74 | -- | 19.30 | -- | -- | 6.36 | -- | -- | 37.54 | -- | 22.60 | -- | -- | -- |
| Alembic Ltd | 1.08bn | 1.43bn | 15.66bn | 305.00 | 10.92 | -- | 18.00 | 14.45 | 5.59 | 5.59 | 4.22 | -- | -- | -- | -- | 3,552,853.00 | -- | 3.40 | -- | 3.52 | 68.66 | 50.21 | 74.35 | 58.12 | -- | 53.28 | -- | 6.08 | 6.39 | -11.87 | -35.23 | 8.84 | 20.12 | 55.18 |
| Holder | Shares | % Held |
|---|---|---|
| American Century Investment Management, Inc.as of 02 Mar 2023 | 7.48k | 0.05% |
| Motilal Oswal Asset Management Co. Ltd.as of 28 Feb 2023 | 45.00 | 0.00% |
